Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

BioNotebook: Versartis VC funding, IPO filing; ANI 2013 earnings; Cardiome's ATM; Eleven's Phase III

18.02.2014 / Scripintelligence

Redwood City, California-based Versartis is developing a once-monthly form of recombinant human growth hormone (rhGH) to treat growth hormone deficiency (GHD) in children. The company is running a Phase IIa clinical trial for its lead program VRS-317 to…

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: